HOME > MARKETS > COMPANY NEWS
  COMPANY NEWS
COMPANY
Mankind Pharma inks definitive pact to acquire majority stake in Armed Cell Therapeutics
Oct-16-2026

Mankind Pharma, through its subsidiary Mankind Pharma (Netherlands) B.V. (Mankind Netherlands), has entered into a definitive agreement under which the company will acquire a majority stake in Armed Cell Therapeutics B.V. (ACTx), a Belgium-incorporated biotechnology company developing next-generation CAR-T (chimeric antigen receptor T-cell) therapies for cancer.

The company will make an additional investment of up to 45 million euro, in one or more tranches in Mankind Netherlands, aggregating to 50 million euro, inclusive of the previously approved investment limit of 5 million euro, which will be utilized to invest 48 million euro in installments in ACTx for acquiring 70% stake. Said investment is part of the company’s long-term strategy to build a global innovation-led pharmaceutical business.

Mankind Pharma is engaged in developing, manufacturing and marketing a diverse range of pharmaceutical formulations across various acute and chronic therapeutic areas, as well as several consumer healthcare products.

  RELATED NEWS >>